Compare Braze Inc (BRZE) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs Novartis AG — how do they compare? Braze Inc trades at $27.77 (market cap $3.24B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 92× Braze Inc's market cap, and Novartis AG pays a 3.02% dividend while Braze Inc pays none. Which is the better fit depends on your goals.
| BRZE | NVS | |
|---|---|---|
Market Cap | $3.24B | $298.18B |
Sector | Technology | Health |
52-Week High | $36.19 | $168.62 |
52-Week Low | $15.79 | $119.31 |
Enterprise Value | $2.93B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Braze (BRZE) trades at $26.54, up 3.23% with bullish technical signals from moving averages. The company shows strong revenue growth trajectory from $238M in 2022 to $593M in 2025, though profitability remains elusive with a -15.51% net margin. Recent Q1 2027 earnings met expectations at $0.10 per share, while analyst sentiment remains overwhelmingly positive with 24 buy ratings and a $34.78 consensus target representing 31% upside potential.
The investment case hinges on Braze's accelerating revenue growth and market leadership in customer engagement software, offset by persistent losses and insider selling. While technical indicators support near-term momentum, execution on profitability remains the key catalyst for sustained upside. Risks include competitive pressures and the company's ability to convert growth into sustainable earnings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
